Photo of George A. Rozanski, PhD

Selected Expertise

  • Damages estimation
  • Econometrics
  • Industrial organization
  • Joint ventures
  • Mergers and acquisitions
  • Monopolization
  • Price-fixing
  • Single-firm conduct

Selected Industries

  • Aerospace
  • Agricultural chemicals
  • Banking and financial services
  • Beer, wine, and spirits
  • Biotechnology
  • Cement and ready-mix concrete
  • Chemicals and specialty chemicals
  • Construction materials
  • Defense
  • Differentiated consumer products
  • Financial services
  • Food and beverage
  • Healthcare
  • Manufacturing
  • Payment cards
  • Securities
  • Seeds and transgenic traits

George A. Rozanski, PhD


George Rozanski has more than 25 years of experience in antitrust analysis.  He consults on the competitive effects of mergers and acquisitions and provides antitrust analysis of alleged anticompetitive conduct, including vertical restraints, IP licensing practices, and price-fixing. Dr. Rozanski′s expertise includes the use of econometrics for demand estimation and merger simulation. He has substantial experience analyzing candidate theories of competitive effects in a wide range of industries, both in civil litigation and before US antitrust agencies.

Prior to joining Bates White, Dr. Rozanski served as Chief of the Economic Regulatory Section of the Antitrust Division of the US Department of Justice. In that role, Dr. Rozanski analyzed proposed mergers and acquisitions, single-firm conduct, and proposed changes in economic regulations and legislation that could affect competition and market outcomes. He had responsibility for conducting, supervising, and presenting the agency’s economic analysis in numerous investigations and litigations involving a wide variety of industries, including telecommunications, banking and financial services, intermediate capital goods, differentiated consumer products, Internet music and video distribution services, financial trading platforms, pharmaceuticals, medical devices, steel, defense, and homogeneous manufactured goods.

Dr. Rozanski earned his SB in economics from the Massachusetts Institute of Technology prior to obtaining his MA and PhD in economics from Harvard.

Selected Experience

  • On behalf of DuPont, analyzed likely competitive effects of its proposed merger with Dow Chemical in a wide range of markets, including seeds and transgenic traits, agricultural chemicals, and specialty polymers. Assisted the parties in responding to requests for information and analysis from agencies in multiple jurisdictions, including the United States, EU, Canada, Brazil, and China. Authored several submissions to Department of Justice (“DOJ”) and appeared before DOJ numerous times to present analysis.
  • On behalf of Express Scripts, provided analysis for its acquisition of MyMatrixx. Both firms provide pharmacy benefits for workers’ compensation cases. Assessed the extent of head-to-head competition and examined win-loss data and competition in the workers’ compensation area. Previously provided analysis on behalf of Express Scripts in it $29 billion acquisition of Medco Health Solutions, which the FTC unconditionally approved after an eight-month investigation. In a private challenge to the latter merger, filed a declaration in US District Court arguing that the merger did not lead to anticompetitive effects in any relevant market; the initial and an amended complaint from Medco were dismissed.
  • On behalf of parties seeking to combine their purchasing of generic pharmaceuticals, co-led a team in performing detailed economic analysis to assess whether the expanded Group Purchasing Organization would have anticompetitive buyer market power, also referred to as monopsony power. Work included an analysis of the combined share of the two parties in each product, an examination of the ability of manufacturers to switch productive assets to alternative uses, and an assessment of the bargaining strength of buyers and sellers. The transaction was finalized in May 2017.
  • On behalf of CEMEX, S.A.B. de C.V. (“CEMEX”) and Grupo Cementos de Chihuahua, S.A.B. de C.V. (“GCC”), conducted analysis presented to the Federal Trade Commission in support of a transfer of manufacturing and distribution assets for cement from CEMEX to GCC.
  • Working on behalf of merging hospitals, identified competitive overlaps, assessed relevant markets, and analyzed likely competitive effects. Presented findings to the FTC and California State Attorney General’s Office. After review, the merger was not challenged.

  • On behalf of Holcim Ltd. and Lafarge SA, which proposed a $25 billion merger that would create the world’s largest cement manufacturer, analyzed potential competitive effects in both the United States and Canada for aggregates, ready-mix concrete, and cement. Provided ongoing advice to the parties throughout the regulatory approval process and presented econometric analyses to both the FTC and the Competition Bureau of Canada (“CBC”). This analysis showed that likely merger effects needed to be evaluated based on a dynamic analysis accounting for the possibility of supply responses. FTC and CBC approved the merger after the parties agreed to certain asset divestitures. For more information, read the press release.
  • Worked on behalf of Dr. Oetker to analyze the competitive effects of its proposed acquisition of McCain Foods’ North American frozen pizza business. Submitted analysis to the Competition Bureau of Canada investigating the likelihood of unilateral effects. The Bureau cleared the acquisition without the issuance of a supplemental information request.
  • On behalf of Thermo Fisher Scientific, advised on the likely competitive effects of its proposed $13.6 billion acquisition of Life Technologies, firms that provide analytical and laboratory services and products. Due to these firms’ global presence, multiple antitrust agencies around the world, including the FTC, reviewed the proposed acquisition. Bates White performed rigorous analyses on horizontal and vertical issues related to the transaction, including a theoretical and empirical analysis of possible vertical effects, based in part on a retrospective study of previous mergers. Bates White also provided consulting support regarding competition issues involved in the European and Chinese investigations of the acquisition. The transaction was approved by all the relevant competition agencies after Thermo Fisher agreed to divest three business units.
  • Conducted detailed economic analysis on behalf of Eli Lilly in connection with its $5.4 billion acquisition of Novartis Animal Health. Both firms were active in developing and marketing animal health products, including medications used to treat pets and livestock. Bates White assessed overlaps in several areas, and presented results of its analysis to the FTC. The FTC approved the merger after an eight month investigation, with divestiture required in one product area, canine parasiticides.
  • On behalf of American Express, analyzed terms in Amex’s contracts with merchants. Provided support for expert testimony on behalf of American Express in its litigation with the DOJ. These terms were alleged to be anticompetitive by DOJ and several states, as well as by several direct action merchants in two different matters (EDNY 10-CV-04496 and EDNY 11-MD-02221). Contributed to the appeal brief after the US District Court for the Eastern District of New York found against Amex. The US Court of Appeals for the Second Circuit subsequently reversed the earlier decision and remanded the case with instructions to enter judgment in favor of Amex.
  • Provided liability and damages analysis for Dupont in its litigation against Monsanto regarding alleged antitrust and intellectual property violations. Monsanto originally sued DuPont and its Pioneer subsidiary for infringing Monsanto’s Roundup Ready soybean patent. DuPont countersued, accusing Monsanto of antitrust violations and of fraudulently obtaining the patent. The parties agreed to dismiss antitrust and patent lawsuits filed against each other as part of a broader licensing agreement.
  • Provided support for expert testimony on damages on behalf of American Airlines, which alleged anticompetitive conduct by Sabre in markets for airline ticket booking services. Similar allegations were at issue in a suit filed against Sabre and Travelport in US District Court. American and Sabre settled their dispute in state court and renewed their existing distribution agreement for multiple years. American received a monetary settlement and continued to pursue its direct connect initiative. Settlement was also reached in US District Court.
  • On behalf of Constellation Brands, analyzed the competitive effects of Anheuser-Busch InBev and Grupo Modelo’s proposed divestiture of brewery and distribution assets to Constellation in response to DOJ's concerns about their proposed merger. DOJ ultimately accepted the proposed divestiture package and approved the merger.
  • Provided analysis on behalf of Grifols in connection with its acquisition of Talecris, both companies involved in the manufacture and sale of plasma-derived therapies used to treat a range of medical conditions. Evaluated possible coordinated effects concerns and assessed the merger specificity of claimed efficiencies in analysis presented to the FTC. FTC approved the transaction after Grifols agreed to a consent decree with provisions to facilitate entry.
  • In Omnicare v. United Health, served as a testifying expert for United Health to assess damages in a lawsuit alleging that premerger coordination led to the joint exercise of monopsony power. Performed rigorous econometric analysis to simulate but-for pricing and estimate total damages for a range of but-for scenarios. Analysis revealed premerger coordination likely would not have a significant impact.
  • Provided analysis to Delta Air Lines and Northwest Airlines in connection with their proposed merger which was under investigation by DOJ. Identified antitrust risks, conducted a retrospective merger analysis on the airline industry, and coauthored a white paper that analyzed likely merger price effects and that was presented to DOJ.